Literature DB >> 23195778

Outcomes in patients treated with mastectomy for ductal carcinoma in situ.

Dawn Owen1, Scott Tyldesley, Cheryl Alexander, Caroline Speers, Pauline Truong, Alan Nichol, Elaine S Wai.   

Abstract

PURPOSE: To examine, in a large, population-based cohort of women, the risk factors for recurrence after mastectomy for pure ductal carcinoma in situ (DCIS) and to identify which patients may benefit from postmastectomy radiation therapy. METHODS AND MATERIALS: Data were analyzed for 637 subjects with pure DCIS, diagnosed between January 1990 and December 1999, treated initially with mastectomy. Locoregional relapse (LRR), breast cancer-specific survival, and overall survival were described using the Kaplan-Meier method. Reported risk factors for LRR (age, margins, size, Van Nuys Prognostic Index, grade, necrosis, and histologic subtype) were analyzed by univariate (log-rank) and multivariate (Cox modeling) methods.
RESULTS: Median follow-up was 12.0 years. Characteristics of the cohort were median age 55 years, 8.6% aged ≤ 40 years, 30.5% tumors >4 cm, 42.5% grade 3 histology, 37.7% multifocal disease, and 4.9% positive margins. At 10 years, LRR was 1.0%, breast cancer-specific survival was 98.0%, and overall survival was 90.3%. All recurrences (n=12) involved ipsilateral chest wall disease, with the majority being invasive disease (11 of 12). None of the 12 patients with recurrence died of breast cancer; all were successfully salvaged (median follow-up of 4.4 years). Ten-year LRR was higher with age ≤ 40 years (7.5% vs 1.5%; P=.003).
CONCLUSION: Mastectomy provides excellent locoregional control for DCIS. Routine use of postmastectomy radiation therapy is not justified. Young age (≤40 years) predicts slightly higher LRR, but possibly owing to the small number of cases with multiple risk factors for relapse, a subgroup with a high risk of LRR (ie, approximately 15%) was not identified.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23195778     DOI: 10.1016/j.ijrobp.2012.10.020

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  Impact of Age on Locoregional and Distant Recurrence After Mastectomy for Ductal Carcinoma In Situ With or Without Microinvasion.

Authors:  Anita Mamtani; Faina Nakhlis; Stephanie Downs-Canner; Emily C Zabor; Monica Morrow; Tari A King; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2019-08-22       Impact factor: 5.344

Review 2.  Current management of lesions associated with an increased risk of breast cancer.

Authors:  Monica Morrow; Stuart J Schnitt; Larry Norton
Journal:  Nat Rev Clin Oncol       Date:  2015-01-27       Impact factor: 66.675

3.  Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ.

Authors:  Megan E Tesch; Shoshana M Rosenberg; Laura C Collins; Julia S Wong; Laura Dominici; Kathryn J Ruddy; Rulla Tamimi; Lidia Schapira; Virginia F Borges; Ellen Warner; Steven E Come; Ann H Partridge
Journal:  Ann Surg Oncol       Date:  2022-08-12       Impact factor: 4.339

Review 4.  Ductal Carcinoma In Situ of the Breast: Evaluating the Role of Radiation Therapy in the Management and Attempts to Identify Low-risk Patients.

Authors:  Chirag Shah; Frank A Vicini; Sameer Berry; Thomas B Julian; John Ben Wilkinson; Simona F Shaitelman; Atif Khan; Steven E Finkelstein; Neal Goldstein
Journal:  Am J Clin Oncol       Date:  2015-10       Impact factor: 2.339

5.  Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy.

Authors:  Annette M Molinaro; Jennette D Sison; Britt-Marie Ljung; Thea D Tlsty; Karla Kerlikowske
Journal:  Breast Cancer Res Treat       Date:  2016-05-04       Impact factor: 4.872

6.  Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted?

Authors:  Elizabeth Fitzsullivan; Sara A Lari; Benjamin Smith; Abigail S Caudle; Savitri Krishnamurthy; Anthony Lucci; Elizabeth A Mittendorf; Gildy V Babiera; Dalliah M Black; Jamie L Wagner; Isabelle Bedrosian; Wendy Woodward; Sarah M Gainer; Rosa Hwang; Funda Meric-Bernstam; Kelly K Hunt; Henry M Kuerer
Journal:  Ann Surg Oncol       Date:  2013-08-23       Impact factor: 5.344

7.  Treatment of Ductal Carcinoma in Situ: Considerations for Tailoring Therapy in the Contemporary Era.

Authors:  Anita Mamtani; Kimberly J Van Zee
Journal:  Curr Breast Cancer Rep       Date:  2020-02-24

8.  Close or positive resection margins are not associated with an increased risk of chest wall recurrence in women with DCIS treated by mastectomy: a population-based analysis.

Authors:  Jonathan Klein; Iwa Kong; Lawrence Paszat; Sharon Nofech-Mozes; Wedad Hanna; Deva Thiruchelvam; Steven A Narod; Refik Saskin; Susan J Done; Naomi Miller; Bruce Youngson; Alan Tuck; Sandip Sengupta; Leela Elavathil; Prashant A Jani; Elzbieta Slodkowska; Michel Bonin; Eileen Rakovitch
Journal:  Springerplus       Date:  2015-07-10

9.  Can titanium mesh influence local recurrence management after implant-based breast reconstruction?

Authors:  Egidio Riggio; Camelia Chifu; Gabriele Martelli; Cristina Ferraris
Journal:  Springerplus       Date:  2015-09-04

10.  Treatment outcome of ductal carcinoma in situ patients treated with postoperative radiation therapy.

Authors:  Yu Jin Lim; Kyubo Kim; Eui Kyu Chie; Wonshik Han; Dong Young Noh; Sung W Ha
Journal:  Radiat Oncol J       Date:  2014-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.